Targeting miRNAs and Other Non-Coding RNAs as a Therapeutic Approach: An Update
Since the discovery of the first microRNAs (miRNAs, miRs), the understanding of miRNA biology has expanded substantially. miRNAs are involved and described as master regulators of the major hallmarks of cancer, including cell differentiation, proliferation, survival, the cell cycle, invasion, and me...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-04-01
|
| Series: | Non-Coding RNA |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2311-553X/9/2/27 |
| _version_ | 1797604034940502016 |
|---|---|
| author | Emine Bayraktar Recep Bayraktar Hulya Oztatlici Gabriel Lopez-Berestein Paola Amero Cristian Rodriguez-Aguayo |
| author_facet | Emine Bayraktar Recep Bayraktar Hulya Oztatlici Gabriel Lopez-Berestein Paola Amero Cristian Rodriguez-Aguayo |
| author_sort | Emine Bayraktar |
| collection | DOAJ |
| description | Since the discovery of the first microRNAs (miRNAs, miRs), the understanding of miRNA biology has expanded substantially. miRNAs are involved and described as master regulators of the major hallmarks of cancer, including cell differentiation, proliferation, survival, the cell cycle, invasion, and metastasis. Experimental data indicate that cancer phenotypes can be modified by targeting miRNA expression, and because miRNAs act as tumor suppressors or oncogenes (oncomiRs), they have emerged as attractive tools and, more importantly, as a new class of targets for drug development in cancer therapeutics. With the use of miRNA mimics or molecules targeting miRNAs (i.e., small-molecule inhibitors such as anti-miRS), these therapeutics have shown promise in preclinical settings. Some miRNA-targeted therapeutics have been extended to clinical development, such as the mimic of miRNA-34 for treating cancer. Here, we discuss insights into the role of miRNAs and other non-coding RNAs in tumorigenesis and resistance and summarize some recent successful systemic delivery approaches and recent developments in miRNAs as targets for anticancer drug development. Furthermore, we provide a comprehensive overview of mimics and inhibitors that are in clinical trials and finally a list of clinical trials based on miRNAs. |
| first_indexed | 2024-03-11T04:40:29Z |
| format | Article |
| id | doaj.art-87e79474a167477aaf1330b8c29a3af9 |
| institution | Directory Open Access Journal |
| issn | 2311-553X |
| language | English |
| last_indexed | 2024-03-11T04:40:29Z |
| publishDate | 2023-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Non-Coding RNA |
| spelling | doaj.art-87e79474a167477aaf1330b8c29a3af92023-11-17T20:44:36ZengMDPI AGNon-Coding RNA2311-553X2023-04-01922710.3390/ncrna9020027Targeting miRNAs and Other Non-Coding RNAs as a Therapeutic Approach: An UpdateEmine Bayraktar0Recep Bayraktar1Hulya Oztatlici2Gabriel Lopez-Berestein3Paola Amero4Cristian Rodriguez-Aguayo5Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USAUTHealth Houston Graduate School of Biomedical Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USADepartment of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USADepartment of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USADepartment of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USADepartment of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USASince the discovery of the first microRNAs (miRNAs, miRs), the understanding of miRNA biology has expanded substantially. miRNAs are involved and described as master regulators of the major hallmarks of cancer, including cell differentiation, proliferation, survival, the cell cycle, invasion, and metastasis. Experimental data indicate that cancer phenotypes can be modified by targeting miRNA expression, and because miRNAs act as tumor suppressors or oncogenes (oncomiRs), they have emerged as attractive tools and, more importantly, as a new class of targets for drug development in cancer therapeutics. With the use of miRNA mimics or molecules targeting miRNAs (i.e., small-molecule inhibitors such as anti-miRS), these therapeutics have shown promise in preclinical settings. Some miRNA-targeted therapeutics have been extended to clinical development, such as the mimic of miRNA-34 for treating cancer. Here, we discuss insights into the role of miRNAs and other non-coding RNAs in tumorigenesis and resistance and summarize some recent successful systemic delivery approaches and recent developments in miRNAs as targets for anticancer drug development. Furthermore, we provide a comprehensive overview of mimics and inhibitors that are in clinical trials and finally a list of clinical trials based on miRNAs.https://www.mdpi.com/2311-553X/9/2/27microRNAmiRNAcancerdrug deliveryresistancetherapeutics |
| spellingShingle | Emine Bayraktar Recep Bayraktar Hulya Oztatlici Gabriel Lopez-Berestein Paola Amero Cristian Rodriguez-Aguayo Targeting miRNAs and Other Non-Coding RNAs as a Therapeutic Approach: An Update Non-Coding RNA microRNA miRNA cancer drug delivery resistance therapeutics |
| title | Targeting miRNAs and Other Non-Coding RNAs as a Therapeutic Approach: An Update |
| title_full | Targeting miRNAs and Other Non-Coding RNAs as a Therapeutic Approach: An Update |
| title_fullStr | Targeting miRNAs and Other Non-Coding RNAs as a Therapeutic Approach: An Update |
| title_full_unstemmed | Targeting miRNAs and Other Non-Coding RNAs as a Therapeutic Approach: An Update |
| title_short | Targeting miRNAs and Other Non-Coding RNAs as a Therapeutic Approach: An Update |
| title_sort | targeting mirnas and other non coding rnas as a therapeutic approach an update |
| topic | microRNA miRNA cancer drug delivery resistance therapeutics |
| url | https://www.mdpi.com/2311-553X/9/2/27 |
| work_keys_str_mv | AT eminebayraktar targetingmirnasandothernoncodingrnasasatherapeuticapproachanupdate AT recepbayraktar targetingmirnasandothernoncodingrnasasatherapeuticapproachanupdate AT hulyaoztatlici targetingmirnasandothernoncodingrnasasatherapeuticapproachanupdate AT gabriellopezberestein targetingmirnasandothernoncodingrnasasatherapeuticapproachanupdate AT paolaamero targetingmirnasandothernoncodingrnasasatherapeuticapproachanupdate AT cristianrodriguezaguayo targetingmirnasandothernoncodingrnasasatherapeuticapproachanupdate |